The Growth in the flow cytometry market is largely driven by the rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, increasing incorporation of AI platforms in flow cytometry workflows, and increasing advancements in flow cytometry software. However, the high cost of flow cytometry products is a major factor hampering the growth of the market.
The flow cytometry market is expected to register a CAGR of 8.1% to reach USD 6.3 Billion in 2026 from USD 4.3 Billion in 2021.
Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584
Scope of the Report
This research report categorizes the flow cytometry market based on technology, product and service, application, end user, and region.
By Technology
Cell-based Flow Cytometry
Bead-based Flow Cytometry
By Product and Service
Reagents and Consumables
Instruments
Cell Analyzers
High-range
Mid-range
Low-range
Cell Sorters
High-range
Mid-range
Low-range
Services
Software
Accessories
By Application
Research Applications
Pharmaceuticals and Biotechnology
Drug Discovery
Stem Cell Research
In Vitro Toxicity Testing
Immunology
Apoptosis
Cell Cycle Analysis
Cell Viability
Cell Counting
Other Research Applications
Clinical Applications
Hematology
Organ Transplantation
Other Clinical Applications
Industrial Applications
By End User
Academic & Research Institutes
Hospitals & Clinical Testing Laboratories
Pharmaceutical & Biotechnology Companies
By Region
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Rest of Europe (RoE)
Asia Pacific
Japan
China
India
Australia
South Korea
Rest of the Asia Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (Rest of LATAM)
Middle East and Africa
Market Segmentation:-
On the basis of technology, the global flow cytometry market is segmented into cell-based and bead-based flow cytometry. The bead-based flow cytometry segment is estimated to witness the highest growth during the forecast period. This technology offers various procedural advantages over other cell-based assays, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.
In this report, the flow cytometry market for clinical applications is segmented into organ & tissue transplantations, cancer diagnostics, immunodeficiency diseases, hematology, and other clinical applications. Flow cytometry can be applied to cancer studies at every stage by measuring the amount of DNA in cancer cells, analyzing tumor cell proliferation, and immunophenotyping hematological malignancies. In addition, flow cytometry tools are used to determine the malignancy of a tumor by analyzing and enumerating a number of chromosomes and can thus be used to detect cancerous cells.
Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584
Regional Analysis: -
In 2020, the Asia Pacific region accounted for the fasted growing region of the market. The APAC market is expected to offer significant growth opportunities to key market players during the forecast period. Countries in this region are witnessing sustained growth in their GDPs and the disposable incomes of their middle-class population.
Top Key Players: -
The major players operating in the flow cytometry market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Luminex Corporation (US), Agilent Technologies, Inc. (US), Sony Group Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec GmbH (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux S.A. (France), Cytonome/ ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences, Inc. (US), Union Biometrica, Inc. (US), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), NEXCELOM BIOSCIENCE LLC (US), BennuBio Inc. (US), ORFLO Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands).
Comments